Sugi Predict

Sugi Predict / Compounds / SCHEMBL10077232

SCHEMBL10077232

SCHEMBL10077232

CCCc1cc(C)nn1C

nearest known ligand 0.40

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ KCNH2 Q12809 12/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ GRIN2B Q13224 1/20 0.39
▸ P2RX7 Q99572 1/20 0.38
▸ DAO P14920 1/20 0.37
▸ MPO P05164 1/20 0.35
▸ GLS O94925 1/20 0.35
▸ FFAR1 O14842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14424414 0.88 MEN1 (0.44) MEN1KMT2AKCNH2GRIN2BP2RX7
SCHEMBL256691 0.86 — —
SCHEMBL19304378 0.84 GPR84 (0.42) MEN1KMT2AKCNH2GRIN2BP2RX7
SCHEMBL8234799 0.81 TDP1 (0.41) KCNH2GRIN2BP2RX7DAOMPO
SCHEMBL27677078 0.81 KCNH2 (0.39) KCNH2SMN1; SMN2GRIN2BP2RX7DAO
SCHEMBL19634920 0.81 P2RX7 (0.40) KCNH2SMN1; SMN2GRIN2BP2RX7DAO
SCHEMBL14537632 0.81 KCNH2 (0.39) KCNH2SMN1; SMN2GRIN2BP2RX7DAO
SCHEMBL23403192 0.77 GPR84 (0.32) MEN1KMT2A
SCHEMBL18255992 0.76 KCNH2 (0.38) KCNH2GRIN2BP2RX7DAOMPO
Hydrochloric Acid SCHEMBL1193206 0.76 KCNH2 (0.43) KCNH2SMN1; SMN2GRIN2BP2RX7DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230123591-A1 TGF-ß INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2023-04-20 — — US disclosed
US-20230045960-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-02-16 — — US disclosed
EP-3277673-B1 TGF-BETA INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2022-05-04 — — EP disclosed
US-20200289456-A1 METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE SEQUOIA PHARMACEUTICALS, INC., 2020-09-17 — — US disclosed
US-10316028-B2 Orexin receptor antagonists HEPTARES THERAPEUTICS LIMITED (GB) 2019-06-11 — — US disclosed
WO-2016191449-A1 ANGIOGENESIS USING STIMULATED PLACENTAL STEM CELLS ANTHROGENESIS CORPORATION (US) 2016-12-01 — — WO disclosed
US-20120225907-A1 BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS ASTRAZENECA AB (SE) 2012-09-06 — — US disclosed
US-20120028973-A1 NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) 2012-02-02 — — US disclosed
US-7902373-B2 asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide PFIZER INC (US) 2011-03-08 — — US disclosed
US-20080312435-A1 Imine Compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-18 — — US disclosed
US-20080312435-A1 Imine Compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-18 — — US disclosed
US-20080146569-A1 Nicotinamide Derivatives PFIZER INC. 2008-06-19 — — US disclosed
US-7375102-B2 Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use AMGEN SF, LLC (US) 2008-05-20 — — US disclosed
WO-2008001070-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-01-03 — — WO disclosed
US-20080004302-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-01-03 — — US disclosed
US-20080004302-A1 Novel Compounds ASTRAZENECA AB (SE) 2008-01-03 — — US disclosed
US-20070298966-A1 Fungicidal Combinations of Active Ingredients BAYERCROPSCIENCE AG (DE) 2007-12-27 — — US disclosed
US-7271271-B2 Imidazolo-related compounds, compositions and methods for their use AMGEN SF, LLC (US) 2007-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312435-A1 Imine Compound CNR1, CNR2, HRH4 MEN1 761/4885KMT2A 2604/4885KCNH2 194/4885
US-20230045960-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C MEN1 4833/4885KMT2A 2341/4885KCNH2 2725/4885
US-20120225907-A1 BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC5 MEN1 1113/4885KMT2A 87/4885KCNH2 1598/4885
US-10316028-B2 Orexin receptor antagonists HCRTR2, HCRTR1, NPY4R MEN1 3296/4885KMT2A 1060/4885KCNH2 2267/4885
US-20200289456-A1 METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE HCCS, CYP2E1, CYP7A1 MEN1 4612/4885KMT2A 2347/4885KCNH2 4309/4885
US-20080146569-A1 Nicotinamide Derivatives NNT, NAMPT, NADK MEN1 2003/4885KMT2A 2987/4885KCNH2 2124/4885
US-20120028973-A1 NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY NOX5, MT-ND5, NQO1 MEN1 4341/4885KMT2A 2767/4885KCNH2 3157/4885
US-20070298966-A1 Fungicidal Combinations of Active Ingredients DDT, CYP51A1, CYP4Z1 MEN1 3527/4885KMT2A 1906/4885KCNH2 1406/4885
US-20230123591-A1 TGF-ß INHIBITORS TGFBR1, TGFBR2, TGFB1 MEN1 2534/4885KMT2A 2918/4885KCNH2 3857/4885
US-20080004302-A1 Novel Compounds CYP11B2, CYP11B1, CYP46A1 MEN1 1408/4885KMT2A 4680/4885KCNH2 3681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.